{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:30:36Z","timestamp":1790771436484,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Schweitzer Biotech Company Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Classical swine fever virus (CSFV) and porcine circovirus type 2 (PCV2) are two of the most devastating and economically significant pathogens affecting pig populations worldwide. Administration of a combination of vaccines against swine pathogens has been demonstrated to be as efficacious as the administration of single vaccines. In this study, we developed and tested a novel bivalent subunit vaccine against CSFV and PCV2. The safety and efficacy of this vaccine were demonstrated in mice and specific pathogen-free (SPF) piglets. In addition to investigating the serological responses after immunization, challenge studies with both viruses were also conducted. The results showed that this CSFV\/PCV2 bivalent vaccine elicited a high level of neutralizing antibodies against both viruses and provided protection in challenge studies. In conclusion, the CSFV\/PCV2 bivalent vaccine is safe and effective against CSFV or PCV2 challenge.<\/jats:p>","DOI":"10.1038\/s41598-024-53624-w","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T03:02:17Z","timestamp":1707188537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2"],"prefix":"10.1038","volume":"14","author":[{"given":"Yu-San","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsun\u2011Yung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"53624_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198151","volume":"289","author":"L Ganges","year":"2020","unstructured":"Ganges, L. et al. Classical swine fever virus: the past, present and future. Virus Res. 289, 198151. https:\/\/doi.org\/10.1016\/j.virusres.2020.198151 (2020).","journal-title":"Virus Res."},{"key":"53624_CR2","doi-asserted-by":"publisher","first-page":"14816","DOI":"10.1038\/s41598-019-51473-6","volume":"9","author":"G Lopez-Lorenzo","year":"2019","unstructured":"Lopez-Lorenzo, G. et al. Environmental distribution of Porcine Circovirus Type 2 (PCV2) in swine herds with natural infection. Sci. Rep. 9, 14816. https:\/\/doi.org\/10.1038\/s41598-019-51473-6 (2019).","journal-title":"Sci. Rep."},{"key":"53624_CR3","doi-asserted-by":"publisher","unstructured":"Postel, A., Smith, D. B. & Becher, P. Proposed Update to the Taxonomy of Pestiviruses: Eight Additional Species within the Genus Pestivirus, Family Flaviviridae. Viruses 13, https:\/\/doi.org\/10.3390\/v13081542 (2021).","DOI":"10.3390\/v13081542"},{"key":"53624_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/bs.aivir.2015.03.002","volume":"93","author":"N Tautz","year":"2015","unstructured":"Tautz, N., Tews, B. A. & Meyers, G. The molecular biology of pestiviruses. Adv. Virus Res. 93, 47\u2013160. https:\/\/doi.org\/10.1016\/bs.aivir.2015.03.002 (2015).","journal-title":"Adv. Virus Res."},{"key":"53624_CR5","doi-asserted-by":"publisher","unstructured":"Coronado, L., Perera, C. L., Rios, L., Frias, M. T. & Perez, L. J. A Critical review about different vaccines against classical swine fever virus and their repercussions in endemic regions. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9020154 (2021).","DOI":"10.3390\/vaccines9020154"},{"key":"53624_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/tbed.14117","volume":"69","author":"K Sawai","year":"2022","unstructured":"Sawai, K. et al. Phylogenetic and phylodynamic analysis of a classical swine fever virus outbreak in Japan (2018\u20132020). Transbound Emerg. Dis. 69, 1529\u20131538. https:\/\/doi.org\/10.1111\/tbed.14117 (2022).","journal-title":"Transbound Emerg. Dis."},{"key":"53624_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12917-019-1982-x","volume":"15","author":"L Coronado","year":"2019","unstructured":"Coronado, L. et al. Investigation of chronic and persistent classical swine fever infections under field conditions and their impact on vaccine efficacy. BMC Vet. Res. 15, 247. https:\/\/doi.org\/10.1186\/s12917-019-1982-x (2019).","journal-title":"BMC Vet. Res."},{"key":"53624_CR8","doi-asserted-by":"publisher","unstructured":"Choe, S. et al. Pathogenicity and genetic characterization of vietnamese classical swine fever virus: 2014\u20132018. Pathogens 9, https:\/\/doi.org\/10.3390\/pathogens9030169 (2020).","DOI":"10.3390\/pathogens9030169"},{"key":"53624_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11262-014-1099-z","volume":"49","author":"QZ Lv","year":"2014","unstructured":"Lv, Q. Z., Guo, K. K. & Zhang, Y. M. Current understanding of genomic DNA of porcine circovirus type 2. Virus Genes 49, 1\u201310. https:\/\/doi.org\/10.1007\/s11262-014-1099-z (2014).","journal-title":"Virus Genes"},{"key":"53624_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0300985812450726","volume":"50","author":"T Opriessnig","year":"2013","unstructured":"Opriessnig, T. & Langohr, I. Current state of knowledge on porcine circovirus type 2-associated lesions. Vet. Pathol. 50, 23\u201338. https:\/\/doi.org\/10.1177\/0300985812450726 (2013).","journal-title":"Vet. Pathol."},{"key":"53624_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.vetmic.2016.10.002","volume":"206","author":"Z Afghah","year":"2017","unstructured":"Afghah, Z., Webb, B., Meng, X. J. & Ramamoorthy, S. T. years of PCV2 vaccines and vaccination: Is eradication a possibility?. Vet. Microbiol. 206, 21\u201328. https:\/\/doi.org\/10.1016\/j.vetmic.2016.10.002 (2017).","journal-title":"Vet. Microbiol."},{"key":"53624_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","volume":"36","author":"J Dumont","year":"2016","unstructured":"Dumont, J., Euwart, D., Mei, B., Estes, S. & Kshirsagar, R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit. Rev. Biotechnol. 36, 1110\u20131122. https:\/\/doi.org\/10.3109\/07388551.2015.1084266 (2016).","journal-title":"Crit. Rev. Biotechnol."},{"key":"53624_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.virol.2011.08.025","volume":"420","author":"BK Gavrilov","year":"2011","unstructured":"Gavrilov, B. K. et al. Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins. Virology 420, 135\u2013145. https:\/\/doi.org\/10.1016\/j.virol.2011.08.025 (2011).","journal-title":"Virology"},{"key":"53624_CR14","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1128\/jvi.69.10.6479-6486.1995","volume":"69","author":"M K\u00f6nig","year":"1995","unstructured":"K\u00f6nig, M., Lengsfeld, T., Pauly, T., Stark, R. & Thiel, H. J. Classical swine fever virus: Independent induction of protective immunity by two structural glycoproteins. J. Virol. 69, 6479\u20136486 (1995).","journal-title":"J. Virol."},{"key":"53624_CR15","doi-asserted-by":"crossref","unstructured":"Moormann, R., Bouma, A., Kramps, J., Terpstra, C. & HJ., D. S. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Vet. Microbiol. 73(2\u20133), 209\u2013219 (2000).","DOI":"10.1016\/S0378-1135(00)00146-2"},{"key":"53624_CR16","doi-asserted-by":"publisher","unstructured":"Sordo-Puga, Y. et al. Porvac((R)) Subunit vaccine E2-CD154 induces remarkable rapid protection against classical swine fever virus. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9020167 (2021).","DOI":"10.3390\/vaccines9020167"},{"key":"53624_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tvjl.2010.06.015","volume":"189","author":"K Lyoo","year":"2011","unstructured":"Lyoo, K. et al. Comparative efficacy of three commercial PCV2 vaccines in conventionally reared pigs. Vet. J. 189, 58\u201362. https:\/\/doi.org\/10.1016\/j.tvjl.2010.06.015 (2011).","journal-title":"Vet. J."},{"issue":"1","key":"53624_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1292\/jvms.09-0314","volume":"72","author":"Y Takahagi","year":"2010","unstructured":"Takahagi, Y., Toki, S., Nishiyama, Y., Morimatsu, F. & Murakami, H. Differential effects of porcine circovirus type 2 (PCV2) vaccination on PCV2 genotypes at Japanese pig farms. J. Vet. Med. Sci 72(1), 35\u201341 (2010).","journal-title":"J. Vet. Med. Sci"},{"key":"53624_CR19","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.vaccine.2015.05.056","volume":"33","author":"LJ Guo","year":"2015","unstructured":"Guo, L. J. et al. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein. Vaccine 33, 3752\u20133757. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.056 (2015).","journal-title":"Vaccine"},{"key":"53624_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.vetmic.2015.02.027","volume":"177","author":"J Jeong","year":"2015","unstructured":"Jeong, J., Park, C., Choi, K. & Chae, C. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b. Vet. Microbiol. 177, 43\u201352. https:\/\/doi.org\/10.1016\/j.vetmic.2015.02.027 (2015).","journal-title":"Vet. Microbiol."},{"key":"53624_CR21","doi-asserted-by":"publisher","unstructured":"Fukai, K., Nishi, T., Masujin, K., Yamada, M. & Ikezawa, M. Quantitative analysis of viremia and viral shedding in pigs infected experimentally with classical swine fever virus isolates obtained from recent outbreaks in Japan. Vet. Res. 54, https:\/\/doi.org\/10.1186\/s13567-023-01215-4 (2023).","DOI":"10.1186\/s13567-023-01215-4"},{"key":"53624_CR22","doi-asserted-by":"publisher","unstructured":"Perez, L. J., Diaz de Arce, H., Percedo, M. I., Dominguez, P. & Frias, M. T. First report of porcine circovirus type 2 infections in Cuba. Res. Vet. Sci. 88, 528\u2013530, https:\/\/doi.org\/10.1016\/j.rvsc.2009.11.014 (2010).","DOI":"10.1016\/j.rvsc.2009.11.014"},{"key":"53624_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12917-020-02718-4","volume":"17","author":"Z Ma","year":"2021","unstructured":"Ma, Z. et al. Epidemiological investigation of porcine circovirus type 2 and its coinfection rate in Shandong province in China from 2015 to 2018. BMC Vet. Res. 17, 17. https:\/\/doi.org\/10.1186\/s12917-020-02718-4 (2021).","journal-title":"BMC Vet. Res."},{"key":"53624_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13567-016-0405-2","volume":"47","author":"S Oliver-Ferrando","year":"2016","unstructured":"Oliver-Ferrando, S. et al. Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages. Vet. Res. 47, 121. https:\/\/doi.org\/10.1186\/s13567-016-0405-2 (2016).","journal-title":"Vet. Res."},{"key":"53624_CR25","doi-asserted-by":"publisher","unstructured":"Horsington, J., Witvliet, M., Jacobs, A. A. C. & Segers, R. Efficacy of Simultaneous Intradermal Vaccination of Swine against Porcine Circovirus 2, Porcine Reproductive and Respiratory Syndrome Virus, Mycoplasma hyopneumoniae and Lawsonia intracellularis. Animals (Basel) 11, https:\/\/doi.org\/10.3390\/ani11082225 (2021).","DOI":"10.3390\/ani11082225"},{"key":"53624_CR26","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. Secreted expression of the cap gene of porcine circovirus type 2 in classical swine fever virus C-Strain: Potential of C-Strain used as a vaccine vector. Viruses 9, https:\/\/doi.org\/10.3390\/v9100298 (2017).","DOI":"10.3390\/v9100298"},{"key":"53624_CR27","doi-asserted-by":"publisher","unstructured":"Chen, M.-H. et al. Production of bivalent subunit vaccine for porcine via 2A-like sequence in baculovirus expression vector system. Processes 10, https:\/\/doi.org\/10.3390\/pr10050895 (2022).","DOI":"10.3390\/pr10050895"},{"key":"53624_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13567-023-01181-x","volume":"54","author":"JY Chen","year":"2023","unstructured":"Chen, J. Y., Wu, C. M., Chia, M. Y., Huang, C. & Chien, M. S. A prospective CSFV-PCV2 bivalent vaccine effectively protects against classical swine fever virus and porcine circovirus type 2 dual challenge and prevents horizontal transmission. Vet. Res. 54, 57. https:\/\/doi.org\/10.1186\/s13567-023-01181-x (2023).","journal-title":"Vet. Res."},{"key":"53624_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/elsc.201900147","volume":"20","author":"L Feng","year":"2020","unstructured":"Feng, L., Chen, L., Yun, J. & Cao, X. Expression of recombinant classical swine fever virus E2 glycoprotein by endogenous Txnip promoter in stable transgenic CHO cells. Eng. Life Sci. 20, 320\u2013330. https:\/\/doi.org\/10.1002\/elsc.201900147 (2020).","journal-title":"Eng. Life Sci."},{"key":"53624_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.790121","volume":"12","author":"H Tariq","year":"2021","unstructured":"Tariq, H., Batool, S., Asif, S., Ali, M. & Abbasi, B. H. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front. Microbiol. 12, 790121. https:\/\/doi.org\/10.3389\/fmicb.2021.790121 (2021).","journal-title":"Front. Microbiol."},{"key":"53624_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 19, 59. https:\/\/doi.org\/10.1186\/s12951-021-00806-7 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"53624_CR32","doi-asserted-by":"publisher","unstructured":"Blome, S., Staubach, C., Henke, J., Carlson, J. & Beer, M. Classical swine fever-an updated review. Viruses 9, https:\/\/doi.org\/10.3390\/v9040086 (2017).","DOI":"10.3390\/v9040086"},{"key":"53624_CR33","doi-asserted-by":"publisher","unstructured":"Choe, S. et al. Protection of Piglets with Maternally Derived Antibodies from sows inoculated with an attenuated live marker classical swine fever vaccine (Flc-LOM-BE(rns)). Pathogens 9, https:\/\/doi.org\/10.3390\/pathogens9080608 (2020).","DOI":"10.3390\/pathogens9080608"},{"key":"53624_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1128\/CVI.00418-10","volume":"18","author":"BR Trible","year":"2011","unstructured":"Trible, B. R. et al. Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin. Vaccine Immunol. 18, 749\u2013757. https:\/\/doi.org\/10.1128\/CVI.00418-10 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"53624_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1746-6148-2-6","volume":"2","author":"P Meerts","year":"2006","unstructured":"Meerts, P. et al. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Vet. Res. 2, 6. https:\/\/doi.org\/10.1186\/1746-6148-2-6 (2006).","journal-title":"BMC Vet. Res."},{"key":"53624_CR36","doi-asserted-by":"crossref","unstructured":"Elbers., A. R. W., Bouma., A. & Stegeman., J. A. Quantitative assessment of clinical signs for the detection of classical swine fever outbreaks during an epidemic. Vet. Microbiol. 85, 323\u2013332 (2002).","DOI":"10.1016\/S0378-1135(01)00519-3"},{"key":"53624_CR37","doi-asserted-by":"crossref","unstructured":"Floegel-Niesmann., G., Bunzenthal., C., Fischer., S. & Moennig., V. Virulence of Recent and Former Classical Swine Fever Virus Isolates Evaluated by their Clinical and Pathological Signs. J. Vet. Med. B Infect. Dis. Vet. Public Health 50, 214\u2013220 (2003).","DOI":"10.1046\/j.1439-0450.2003.00663.x"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53624-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T07:03:25Z","timestamp":1707462205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53624-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53624"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-53624-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Schweitzer Biotech Company (SBC) Ltd. is the sponsor of the project. Y.S.C., C.Y.L., C.C.W., T.A.C., Y.H. and C.C. are employees of the SBC. However, the authors declare that the research was conducted with integrity, following all ethical guidelines. C.C. also has a patent pending relating to the bivalent subunit vaccine against CSFV\/PCV2. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2997"}}